

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1-15. Canceled.

1 16. (Currently amended) A method for suppressing the
2 hyperproliferative growth of arterial cells ~~treatment of a hyperproliferative disorder~~ in a
3 patient, the method comprising directly introducing into said arterial cells ~~administering~~
4 ~~to a patient a therapeutically~~ a nucleic acid encoding ~~effective amount~~ ~~does of~~ a fusion
5 polypeptide ~~that~~,
6 wherein said fusion polypeptide comprises an E2F DNA binding domain
7 ~~of a transcription factor~~ and a functional growth suppression domain of a retinoblastoma
8 (RB) polypeptide ;
9 wherein said E2F DNA binding domain lacks a functional cyclin A
10 binding domain; and wherein said fusion polypeptide is expressed in an amount sufficient
11 to attenuate the growth of at least a portion of said arterial cells.

1 17. (Currently amended) The method of claim 16, wherein ~~the fusion~~
2 ~~polypeptide is encoded by a nucleic acid delivered to the patient~~ said nucleic acid is a
3 replication-deficient adenoviral vector.

1 18. (Currently amended) The method of claim 16, wherein ~~the~~
2 ~~transcription factor is E2F~~ at least a portion of said arterial cells endogenously express
3 defective RB protein.

19. (Canceled)

1 20. (Original) The method of claim 16, wherein the RB is RB56.

1 21. (Original) The method of claim 16, wherein the RB is wild type
2 RB56.

1 22. (Previously amended) The method of claim 16, wherein the
2 functional growth suppression domain of the RB polypeptide comprises from about
3 amino acid residue 379 to about amino acid residue 928 (SEQ ID NO:4).

1 23. (Previously amended) The method of claim 16, wherein the
2 functional growth suppression domain of the RB polypeptide comprises at least one
3 substitution of amino acid residues selected from the group consisting of 2, 608, 612,
4 788, 807, and 811.

1 24. (Previously amended) The method of claim 16, wherein the E2F
2 polypeptide comprises about amino acid residues 95 to about 286 (SEQ ID NO:1).

1 25. (Previously amended) The method of claim 16, wherein the E2F
2 polypeptide comprises about amino acid residues 95 to about 194 (SEQ ID NO:1).

1 26. (Previously amended) The method of claim 16, wherein the fusion
2 polypeptide comprises EF2 amino acid residues from about 95 to about 194 (SEQ ID
3 NO:1) operatively linked to RB amino acid residues from about 379 to about 928 (SEQ
4 ID NO:4).

1 27. (Original) The method of claim 18, wherein the E2F-RB fusion
2 polypeptide is expressed under the control of a tissue-specific promoter.

1 28. (Original) The method of claim 27, wherein the tissue specific
2 promoter is a smooth muscle actin promoter.

29. (Canceled)

30. (Canceled)

31-36. (Canceled)

37. (Canceled)

1 38. (New) The method of claim 16, wherein the fusion polypeptide
2 comprises a fusion of about amino acids 95-194 of E2F (SEQ ID NO:1) and about amino
3 acids 379-928 of RB (SEQ ID NO:4); and
4 wherein said fusion polypeptide is encoded by a replication-deficient
5 adenoviral viral vector directly introduced into said arterial cells.

1 39. (New) The method of claim 38, wherein the RB portion of the
2 encoded fusion polypeptide comprises at least one substitution of amino acid residues
3 selected from the group consisting of 608, 612, 788, 807, and 811.

1 40. (New) The method of claim 38, wherein expression of said fusion
2 polypeptide is under control of a cytomegalovirus promoter.

1 41. (New) The method of claim 38, wherein said expression of said
2 fusion polypeptide is under control of a smooth muscle actin promoter.

1 42. (New) The method of claim 16, wherein the fusion polypeptide
2 comprises a fusion of about amino acids 95-286 of E2F (SEQ ID NO:1) and about amino
3 acids 379-928 of RB (SEQ ID NO:4); and
4 wherein said fusion polypeptide is encoded by a replication-deficient
5 adenoviral viral vector directly introduced into said arterial wall cells.

1 43. (New) The method of claim 42, wherein the RB portion of the
2 encoded fusion polypeptide comprises at least one substitution of amino acid residues
3 selected from the group consisting of 608, 612, 788, 807, and 811.

1 44. (New) The method of claim 42, wherein expression of said fusion
2 polypeptide is under control of a cytomegalovirus promoter.

1 45. (New) The method of claim 42, wherein expression of said fusion
2 polypeptide is under control of a tissue-specific promoter.

1 46. (New) The method of any of claims 17, 38 or 43, wherein said
2 adenoviral vector is administered by directly contacting said arterial cells with a stent,
3 wherein said stent is coated with an administration composition comprising said vector.